Ryan Himes

Ryan Himes

Auto-generated profile, based on publicly available information

Ryan Himes

Department of Pediatrics, Baylor College of Medicine, Houston, TX

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
VMVeronique D. Morinville
Veronique D. Morinville
SHSohail Z. Husain
Sohail Z. Husain
HBHarrison Bai
Harrison Bai
BBBradley Barth
Bradley Barth
RARabea Alhosh
Rabea Alhosh
IGINSPPIRE Group
INSPPIRE Group

1 June 2016 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
SKSoma Kumar
Soma Kumar
KOKeith Ooi
Keith Ooi
SWSteven Werlin
Steven Werlin
MAMaisam Abu-El-Haija
Maisam Abu-El-Haija
BBBradley Barth
Bradley Barth
AUAliye Uc
Aliye Uc
Acute recurrent pancreatitis (ARP) and chronic pancreatitis (CP) are poorly understood conditions of childhood.1 Single-center studies estimate that 9% to 35% of children with acute pancreatitis (AP) have recurrent episodes,2-5 and the incidence of CP is approximately 0.5 per 100 000 persons per year in young adults.6,7

1 April 2015 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SSSarah Jane Schwarzenberg
Sarah Jane Schwarzenberg
MBMelena Bellin
Melena Bellin
SHSohail Z. Husain
Sohail Z. Husain
MAMonika Ahuja
Monika Ahuja
BBBradley Barth
Bradley Barth
AUAliye Uc
Aliye Uc

19 October 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RHRyan W. Himes
Ryan W. Himes
CSC. Wayne Smith
C. Wayne Smith
Obesity and its associated comorbidities, termed metabolic syndrome, are increasingly prevalent, and they pose a serious threat to the health of individuals and populations. Gene‐environment interactions have been scrutinized since the kinetics of the increased prevalence of obesity would argue against a purely genetic etiology. Toll‐like receptors (TLRs), widely expressed and highly conserved transmembrane receptors, are at the intersection of diet and metabolism, and may therefore be important determinants of weight gain and its sequellae. We sought specifically to determine the role of Tlr2 in the development of obesity and metabolic syndrome utilizing two dietary models that approximate contemporary diet compositions. Using C57BL/6 Hsd mice (wild type, WT) and mice with a targeted mutation in Tlr2 (Tlr2 ‐/‐ ), we showed that mice lacking TLR2 are substantially protected from diet‐induced adiposity, insulin resistance, hypercholesterolemia, and hepatic steatosis. In adipose tissue, Tlr2 deletion was associated with attenuation of adipocyte hypertrophy, as well as diminished macrophage infiltration and inflammatory cytokine expression.—Himes, R. W., Smith, C. W. Tlr2 is critical for diet‐induced metabolic syndrome in a murine model. FASEB J. 24, 731–739 (2010). www.fasebj.org

1 December 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JSJeffrey B. Schwimmer
Jeffrey B. Schwimmer
JLJoel E. Lavine
Joel E. Lavine
LWLaura A. Wilson
Laura A. Wilson
BNBrent A. Neuschwander-Tetri
Brent A. Neuschwander-Tetri
SXStavra A. Xanthakos
Stavra A. Xanthakos
KYKatherine Yates
Katherine Yates
Background & Aims No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD. Methods We performed a double-masked trial of 169 children with NAFLD activity scores of 4 or higher at 10 centers. From June 2012 to January 2014, the patients were assigned randomly to receive CBDR or placebo twice daily (300 mg for patients weighing ≤65 kg, 375 mg for patients weighing >65 to 80 kg, and 450 mg for patients weighing >80 kg) for 52 weeks. The primary outcome from the intention-to-treat analysis was improvement in liver histology over 52 weeks, defined as a decrease in the NAFLD activity score of 2 points or more without worsening fibrosis; patients without biopsy specimens from week 52 (17 in the CBDR group and 6 in the placebo group) were considered nonresponders. We calculated the relative risks (RR) of improvement using a stratified Cochran–Mantel–Haenszel analysis. Results There was no significant difference between groups in the primary outcome (28% of children in the CBDR group vs 22% in the placebo group; RR, 1.3; 95% confidence interval [CI], 0.8–2.1; P = .34). However, children receiving CBDR had significant changes in prespecified secondary outcomes: reduced mean levels of alanine aminotransferase (reduction, 53 ± 88 U/L vs 8 ± 77 U/L in the placebo group; P = .02) and aspartate aminotransferase (reduction, 31 ± 52 vs 4 ± 36 U/L in the placebo group; P = .008), and a larger proportion had reduced lobular inflammation (36% in the CBDR group vs 21% in the placebo group; RR, 1.8; 95% CI, 1.1–2.9; P = .03). In a post hoc analysis of children weighing 65 kg or less, those taking CBDR had a 4-fold better chance of histologic improvement (observed in 50% of children in the CBDR group vs 13% in the placebo group; RR, 4.0; 95% CI, 1.3–12.3; P = .005). Conclusions In a randomized trial, we found that 1 year of CBDR did not reduce overall histologic markers of NAFLD compared with placebo in children. Children receiving CBDR, however, had significant reductions in serum aminotransferase levels and lobular inflammation. ClinicalTrials.gov no: NCT01529268.

1 August 2017 in The Journal of Pediatrics
Verified
Journal Article
Closed access
KNKimberly P. Newton
Kimberly P. Newton
HFHaruna S. Feldman
Haruna S. Feldman
CCChristina D Chambers
Christina D Chambers
LWLaura Wilson
Laura Wilson
CBCynthia Behling
Cynthia Behling
KYKatherine Yates
Katherine Yates